Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.20.01 | Pituitary – Hypopituitarism | ECE2015

Reduced mortality due to malignant neoplasms in patients receiving long-term GH replacement therapy – a Swedish study based on more than 4000 patient-years

Olsson Daniel S , Nilsson Anna G , Trimpou Penelope , Bengtsson Bengt-AEke , Andersson Eva , Johannsson Gudmundur

Patients with hypopituitarism and untreated growth hormone (GH) deficiency have excess mortality. GH replacement therapy (GHRT) has many beneficial effects, but its impact on mortality has not been proven and there are still safety concerns regarding the potential cancer risk. We have therefore studied the mortality in non-functioning pituitary adenoma (NFPA) patients with and without GHRT. Only patients with NFPA were studied in order to eliminate the influence of the aetiolo...

ea0014oc8.6 | Neuroendocrinology clinical | ECE2007

Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet

Skrtic Stanko , Lennernäs Hans , Nilsson Anna , Bergthorsdottir Ragnhildur , Hedner Thomas , Johannsson Gudmundur

Background: Mortality rate in patients with primary and secondary adrenal insufficiency is increased. A contributing factor could be the dose and the pattern of glucocorticoid replacement therapy. Hydrocortisone administered twice or thrice daily produces high serum peaks and low trough values in-between. A novel, once daily, hydrocortisone modified release tablet with combined immediate and extended release characteristics was developed.Purpose: The aim...

ea0041oc13.3 | Pituitary Clinical | ECE2016

Increased glucocorticoid replacement doses are associated with excess mortality in patients with non-functioning pituitary adenoma

Hammarstrand Casper , Hallen Tobias , Andersson Eva , Skoglund Thomas , Nilsson Anna G , Ragnarsson Oskar , Johannsson Gudmundur , Olsson Daniel S

Background: Patients with secondary adrenal insufficiency have an excess mortality. Data concerning the influence of the glucocorticoid replacement regime on mortality is sparse.Objective: To investigate if the total daily dose of glucocorticoid replacement has an effect on mortality in patients with non-functioning pituitary adenoma (NFPA).Method: Patients with NFPA treated for hypopituitarism in the western region of Sweden were ...

ea0041gp14 | Adrenal (1) | ECE2016

A Phase 3b, open-label, extension study to evaluate the long-term safety of once-daily, dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI)

Nilsson Anna , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Ragnarsson Oskar , Skrtic Stanko , Wahlberg Jeanette , Achenbach Heinrich , Uddin Sharif , Marelli Claudio , Johannsson Gudmundur

Introduction: Glucocorticoid replacement for adrenal insufficiency (AI) remains inadequate, resulting in high morbidity, premature mortality and quality-of-life (QoL) impairment. This study investigated the long-term safety of dual-release hydrocortisone (DR-HC) in patients with primary AI.Methods: AI patients who completed a randomized, 3-month crossover study of once-daily DR-HC versus thrice-daily conventional immediate-release hydrocortisone plus a 6...

ea0032p625 | Growth hormome IGF axis – basic | ECE2013

SNPs within the GH signaling pathway are associated with the fast, but not the long term, IGF1 response to GH replacement therapy in GH deficient adults

Glad Camilla , de Jesus Litenski Barbosa Edna , Filipsson Nystrom Helena , Carlsson Ekander Lena , Nilsson Staffan , Nilsson Anna , Svensson Per-Arne , Johannsson Gudmundur

Introduction: GH deficiency (GHD) in adults is associated with low serum levels of insulin-like growth factor 1 (IGF1) and a deteriorated cardio-metabolic profile. GH replacement therapy (GHRT) increases serum IGF1, an important mediator of the treatment response and safety marker of dose titration. The interindividual variation in treatment response is large and most likely influenced by genetic factors.Aim: The aim of this study was to test the hypothe...

ea0056gp30 | Adrenal clinical | ECE2018

The urinary cortisol metabolome in patients with adrenal insufficiency: dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy

Espiard Stephanie , McQueen Johanna , Sherlock Mark , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Engstrom Britt Eden , Nilsson Anna G , Skrtic Stanko , Wahlberg Jeanette , Stewart Paul M , Johannsson Gudmundur

Introduction: Oral once-daily dual-release hydrocortisone (DR-HC) therapy provides a more physiological cortisol profile than conventional thrice-daily (TID) replacement therapy and has demonstrated improved metabolic profile among patients with adrenal insufficiency (AI). The mechanisms by which this metabolic improvement occurs may be due to less total exposure, changed cortisol time exposure profile, but also modified metabolism of cortisol.Objective:...

ea0056p160 | Steroid metabolism + action | ECE2018

Urinary steroid profile in patients with primary adrenal insufficiency under conventional glucocorticoid replacement: a case control study

Espiard Stephanie , McQueen Johanna , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Nilsson Anna G. , Skrtic Stanko , Wahlberg Jeanette , Sherlock Mark , Stewart Paul M. , Johannsson Gudmundur

Introduction: Primary adrenal insufficiency (PAI) leads to a drastically reduced production of steroids from the adrenal cortex, but a few patients may keep some residual adrenal steroid secretion that may simplify replacement therapy and prevent adrenal crisis. Irrespectively, the conventional glucocorticoid (GC) replacement therapy, using thrice-daily oral hydrocortisone, does not restore the patients’ physiological cortisol profile.Objective: The...